ClinicalTrials.gg
RecruitingNCT06856213ERBIOTAXUpdated Jun 4, 2026

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

A Phase 2 interventional study of Cetuximab and Paclitaxel in Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma, sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Recruiting at 17 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 19 under way, 7 of them phase 3. Cetuximab · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
30th of 84
65 · median 46
Started
2025
with 5 others
Phase 2
41 of 86
6 open now
Primary completion
2028-10
later than 13 of 18 live
Registered
79th of 86
by date

Among the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, this one is the 30th largest by planned enrollment of the 84 interventional ones that give a count, is one of 6 that started in 2025, is one of 41 in phase 2, reaches primary completion later than 13 of the 18 other live ones, and was the 79th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

11 of the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

Squamous cell carcinoma of the head and neck (SCCHN) arises from epithelial cells and occurs in the oral cavity, pharynx and larynx. SCCHN is the seventh most common cancer worldwide with an annual incidence of approximately 90.000 cases per year in Europe.

Recurrent / metastatic SCCHN remains a grievous diagnosis and optimal treatment options after progression to first-line ICI treatment are not determined yet. Previous reports showed that cetuximab plus paclitaxel after progression to ICI therapy may have an enhanced activity as second line after ICI therapy ERBIOTAX is multi-center, open-label, randomized, non-comparative two-arm, phase 2 trial Investigator Initiated Study.

The primary study aims is to evaluate the efficacy of weekly cetuximab combined with paclitaxel (Arm A) or cetuximab monotherapy (Arm B) after progression to pembrolizumab plus platinum / 5-FU. The efficacy of treatment will be assessed through objective response rate (ORR).

Patients will be randomized in a 2:1 ratio to ERBITAX (cetuximab + paclitaxel) and cetuximab, respectively, assigning 2 patients to Arm A and 1 patient to Arm B out of 3 patients. No stratification for the randomization process is planned as this is a non-comparative study. A total of 65 evaluable patients will be included in the trial; 41 in Arm A and 24 in Arm B.

The main hypothesis is that treatment with the cetuximab +/- paclitaxel regimen maybe more effective after immune checkpoint inhibitors (ICI) failure in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Read the detailed description
  1. Objectives

    Primary Objective

    -The study aims to evaluate the efficacy of weekly cetuximab combined with paclitaxel (Arm A) or cetuximab monotherapy (Arm B) after progression to pembrolizumab plus platinum / 5-FU. The efficacy of treatment will be assessed through objective response rate (ORR).

    Secondary Objectives

    • To evaluate clinical outcomes such as disease control rate (DCR), progression free survival (PFS), and overall survival (OS).
    • To evaluate the quality of life of patients with recurrent/metastatic head and neck squamous cell carcinoma treated with cetuximab and paclitaxel or cetuximab monotherapy.
    • To evaluate safety of the intended treatment regimen based on the frequency and severity of adverse events and Treatment-emergent adverse events (TEAEs) assessed by NCI CTCAE v5.0.

    Exploratory objectives

    • To evaluate the genomic/transcriptomic/proteomic alterations in baseline and on-treatment tumor samples.
    • To evaluate ctDNA dynamics between baseline and on-treatment plasma samples. Immunophenotyping of tumor samples.
  2. Endpoints Primary Endpoint Objective response rate (ORR) according to RECIST V1.1 criteria Secondary Efficacy Endpoints

    • Disease Control Rate (DCR)

      . Median PFS

    • Median OS
    • Health-related quality of life (HRQoL), assessed through the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) version 3, the head and neck specific module QLQ-H\&N35 and EuroQol EQ-5D Secondary Safety Endpoints
    • Frequency and severity of adverse events and Treatment-related adverse events (TRAEs) assessed by NCI CTCAE v5.0
    • Rate of completion of C2D8, C4D8 and C6D8 of Cetuximab +/- Paclitaxel Exploratory endpoints
    • Presence of genomic/transcriptomic/proteomic alterations
    • ctDNA dynamics through study treatment
    • Immunophenotype of tumor and blood samples
  3. Study Design The ERBIOTAX trial is a multicenter, open-label, randomized, non-comparative two-cohort, Phase II clinical trial of cetuximab either as monotherapy or in combination with paclitaxel in patients with SCCHN progressing on or after pembrolizumab plus platinum-based chemotherapy as first-line combination therapy. Additional details on the eligibility criteria of the study are found in protocol.

    The primary aim of the study is to evaluate the efficacy of weekly cetuximab combined with paclitaxel (Arm A) or cetuximab monotherapy (Arm B) after progression to pembrolizumab plus platinum / 5-FU. The efficacy of treatment will be assessed through ORR.

    The design includes a screening phase in which patient eligibility is addressed, a treatment phase with cetuximab, either as a single agent or combined with paclitaxel, and a follow-up phase.

    Signed informed consent form (ICF) will be obtained prior to the start of the specified screening window. Procedures conducted as part of the subject's routine clinical management (e.g., blood count determinations and imaging studies) prior to signing of ICF may be used for screening or for defining baseline data, provided these procedures are conducted as specified in the protocol.Patients will be randomized in a 2:1 ratio to ERBITAX and cetuximab, respectively.

  4. Study population The trial will include 65 evaluable patients with recurrent/metastatic head and neck squamous cell carcinoma (41 in group A and 24 in group B).
  5. Study Treatments

Patients will be randomized (2:1 ratio) to cetuximab + paclitaxel (ERBITAX) (Arm A) or to cetuximab monotherapy (Arm B). The complete schedule of treatment is detailed below:

ARM A: Cetuximab 400 mg/m2 initial dose followed by 250 mg/m2 + Paclitaxel 80mg/m2 (D1, D8 and D15 each 3-weeks cycle) for 4 cycles. Then, monotherapy maintenance with cetuximab at a dose of 500 mg/m2 will be administered biweekly (D1 and D15; Q4W) until disease progression or death, unacceptable toxicity or patient withdrawal of consent*.

ARM B: Cetuximab 400 mg/m2 initial dose followed by 250 mg/m2 (D1, D8 and D15 each 3-weeks cycle) for 4 cycles. Then, maintenance with cetuximab at a dose of 500 mg/m2 will be administered biweekly (D1 and D15; Q4W) until disease progression or death, unacceptable toxicity or patient withdrawal of consent.

03

Conditions studied

  • Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Keywords

  • Squamous Cell Carcinoma of the Head and Neck
  • SCCHN
  • Cetuximab
  • Paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

  1. Signed written and voluntary informed consent.
  2. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
  3. Age > 18 years old. Disease characteristics
  4. Have confirmed diagnosis of head and neck squamous cell carcinoma.
  5. The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
  6. Known Human papillomavirus (HPV) status in oropharyngeal primaries and tested by p16 and/or HPV DNA testing by ISH or PCR. Local testing is acceptable.
  7. Have confirmed disease progression per 1.1 on or after receiving platinum / 5-FU and pembrolizumab as therapy for recurrent/ disease. Patients must have assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) based on RECIST 1.1 as assessed by the local site investigator/radiology. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  8. All patients should provide a tumor obtained prior to the start of cetuximab +/- paclitaxel. A newly obtained biopsy -after progression to pembrolizumab + platinum-based chemotherapy - of a tumor lesion not previously irradiated for central biomarker analysis prior to start of study treatment is strongly recommended, but an archival tumor biopsy sample may be acceptable upon discussion with the sponsor.

    A second tumor block (FFPE) sample will be strongly recommended to be collected between C2D1 and before C2D15 .

    Note: Fine needle aspirate [FNA] is not adequate. Repeat samples may be required if adequate (quality and quantity) tissue is not provided. Formalin-fixed, paraffin embedded tissue blocks are preferred to slides

    Patient characteristics

  9. Have a performance status of 0 or 1 on the Performance Scale
  10. Patients must have adequate organ function as determined by the following. Screening labs should be performed within -7 days of treatment initiation:

    a. Hematology

    • Absolute neutrophils > 1.5 x 109/L
    • > 100 x 109/L
    • > 90 g/L
    • Biochemistry
    • \< 1.5 x (ULN)
    • and ALT \< 2.5 x ULN
    • Creatinine or measured or calculated ( can also be used in place of creatinine or CrCl) ≤ 1.5xULN or ≥ 60 mL/min, respectively.
  11. Evidence of status, or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

    1. Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).
    2. Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).
  12. Female subjects of should have a negative blood pregnancy test within 72 hours prior to receiving the first dose of study medication. A urine test can be considered if a blood test is not appropriate.
  13. Female subjects of childbearing potential should be willing to use 2 methods of or be surgically sterile or abstain from heterosexual activity for the course of the study through 180 days after the last dose of study medication (6 months for paclitaxel). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >1 year.

    Note: Abstinence is acceptable if this is the usual lifestyle and preferred method of contraception for the subject.

  14. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 180 days after the last dose of study therapy (6 months for paclitaxel).

Note: Abstinence is acceptable if this is the usual lifestyle and preferred method of contraception for the subject.

Exclusion criteria

Exclusion Criteria:

  1. Patients with tumors of the head and neck region, arising from the nasopharynx, nasal cavity, paranasal sinuses, salivary glands, skin, unknown primary site.
  2. Patients not treated or not progressing to pembrolizumab + platinum / 5-FU as the prior to their enrollment in the study. Progression to platinum / 5-FU plus pembrolizumab or other antiPD-(L)1 agents in combination with other immunotherapies including but not limited to other checkpoint regulatory monoclonal/bispecific antibodies such as anti , anti LAG-3 , anti TIGIT or anti TIM-3 may be allowed upon discussion with the sponsor.
  3. Any previous treatment with paclitaxel and/or cetuximab in the recurrent or setting.
  4. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

    Note: Subjects with previously treated may participate provided they are stable (without evidence of progression by imaging (using the identical imaging modality for each assessment, either MRI or CT scan) for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.

  5. Has a of less than 3 months and/or has rapidly progressing disease (e.g. tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.
  6. History of another primary , except for:

    1. Malignancy treated with curative intent and with no known active disease ≥3 years before the first dose of study drug and of low potential risk for recurrence,
    2. Adequately treated non-melanoma skin cancer without evidence of disease,
    3. Adequately treated carcinoma in situ without evidence of disease.
  7. Any previous surgical treatment of the current cancer (except for a diagnostic ) and no major surgery within 28 days prior to study treatment initiation. Performance of a tracheostomy or placement of a percutaneous gastrostomy tube within the 28 days prior to study treatment initiation will be allowed if the patient is clinically stable with no complications derived from those interventions.
  8. Focal radiotherapy (RT) with palliative intent that is not completed 2 weeks prior to the first dose of Cetuximab +/- Paclitaxel.
  9. History of allergic or reactions to any study drugs or their .
  10. History of allogeneic organ transplant that requires therapeutic and the use of immunosuppressive agents within 28 days of study treatment initiation or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy or grade ≥ 3 infusion reaction.
  11. Any concurrent chemotherapy, biologic, immunologic or hormonal therapy for cancer treatment. Concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable.
  12. Current or prior use of immunosuppressive medication within 7 days prior to starting dosing. The following are exceptions to these criteria:

    1. Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection).
    2. Adrenal replacement steroid > 10 mg daily prednisone equivalent are permitted in the absence of active disease.
    3. Steroids as premedication for hypersensitivity reactions (eg, computed tomography scan premedication).
    4. \< 10 mg prednisone or equivalent are permitted for the treatment of G1 IRAEs.
  13. Any prior unresolved immune-related (ir) AE Grade > 2 not properly controlled as described in the exclusion criteria 14 and considered limiting according to physician criteria.
  14. History of primary immune deficiency. History of organ transplant that requires use of immunosuppressive medications. Subjects who are human immunodeficiency () positive. Participants under definitive treatment for HIV (HAART) with undetectable viral load and >500 CD4+ T lymphocytes per μL at Screening Visit, are allowed.
  15. History of stroke or within the previous 6 months.
  16. Any of the following cardiac abnormalities:

    1. Unstable angina pectoris,
    2. Congestive heart failure ≥ Class 2,
    3. (Fridericia formula) > 450 for males and > 470 ms for females,
    4. Known (LVEF) \< 50,
    5. Unstable cardiac arrhythmia.
  17. Pre-existing neuropathy ≥ Grade 2 per v5.0.
  18. With history of interstitial lung disease, noninfectious pneumonitis, severe , or uncontrolled lung diseases, including pulmonary fibrosis. However, specific cases may be allowed upon discussion with the sponsor.
  19. Has a known history of or is positive for active (defined as hepatitis B surface antigen [HBsAg] reactive) or (defined as HCV RNA [qualitative] is detected).

    Note: HBV DNA must be undetectable and HBsAg negative at Screening Visit. Active chronic hepatitis B on antiviral treatment with a negative viral load and preserved liver function is permitted upon consultation with the sponsor.

    Participants who have had definitive treatment for HCV are permitted if HCV RNA is undetectable at Screening Visit.

  20. Female patients who are pregnant or breast-feeding.
  21. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics 2 weeks before treatment start,
  22. Uncontrolled intercurrent psychiatric illness/social situations that would limit compliance with study requirements.
  23. Any condition that, in the opinion of the Investigator, would interfere with evaluation of the study regimen or interpretation of patient safety or study results.
Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    ARM A (Cetuximab+Paclitaxel)

    Cetuximab 400 mg/m2 initial dose followed by 250 mg/m2 + Paclitaxel 80mg/m2 (D1, D8 and D15 each 3-weeks cycle) for 4 cycles. Then, monotherapy maintenance with cetuximab at a dose of 500 mg/m2 will be administered biweekly (D1 and D15; Q4W) until disease progression or death, unacceptable toxicity or patient withdrawal of consent

    Drug: Cetuximab · Drug: Paclitaxel

  • Experimental
    ARM B (Cetuximab)

    Cetuximab 400 mg/m2 initial dose followed by 250 mg/m2 (D1, D8 and D15 each 3-weeks cycle) for 4 cycles. Then, maintenance with cetuximab at a dose of 500 mg/m2 will be administered biweekly (D1 and D15; Q4W) until disease progression or death, unacceptable toxicity or patient withdrawal of consent.

    Drug: Cetuximab

Interventions

  • Cetuximab 250 mg/m2 will be administered as an intravenous infusion over 60 minutes. Cetuximab loading dose is 400 mg/m2 infusion and will be administered over 120 minutes. During maintenance, cetuximab at 500 mg/m2 will be administered as an intravenous infusion over 120 minutes.

  • Paclitaxel at a dose of 80 mg/m² will be administered after cetuximab as an intravenous infusion over 60 minutes weekly.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) according to RECIST V1.1 criteria

    Objective response rate (ORR) will be Assessed by the investigator through imaging follow-up (CT scan/MRI) using RECIST 1.1. This will be considered as the percentage/proportion of patients with complete response (CR) or partial response (PR) as their overall best response throughout the study period.

    Time frame: Throughout the study period, approximately 24 months

Secondary outcomes

  1. DCR (Disease Control Rate)

    Percentage/proportion of patients with complete response (CR) or partial response (PR), according to ORR definition for the trial, or maintained stable disease (SD) as their overall best response, assessed by imaging follow-up (CT scan/MRI) and RECIST 1.1 criteria. Stable disease should be maintained for at least 4 months to be considered as a DCR event.

    Time frame: Throughout the study period, approximately in a time frame 6 months from the start of treatment

  2. Progression-free surviva (PFS)

    Progression-free survival (PFS): Time from randomization to the date of confirmed PD according to RECIST 1.1. Patients alive and free of events at the date of the analysis will be censored at their last known tumor assessment. Patients who start a new treatment line without progression will be censored on the date of first dose of the subsequent anticancer treatment.

    Time frame: Throughout the study period, at week 8 and every 12 weeks thereafter from start treatment for up to approximately 24 months

  3. Overall survival (OS)

    Overall survival (OS): defined as the time elapsed from randomization until death from any cause. We will assess the median OS, estimated by Kaplan-Meier. Patients alive and free of events at the date of the analysis will be censored at their last known contact. Survival will be assessed by recording patient status at each visit. Patients will be followed up for at least 2 years

    Time frame: Throughout the study period, approximately 24 months from start treatment

  4. Frequency and severity of adverse events and Treatment-related adverse events (TRAEs)

    Frequency and severity of adverse events and Treatment-related adverse events (TRAEs) assessed by NCI CTCAE v5.0 Adverse events (AE) assessment: type, frequency, outcome of adverse events and severe adverse events (SAEs). Actions taken regarding cetuximab and paclitaxel (i.e. treatment interruptions) will be recorded. Serious adverse events (SAEs) assessment: type, frequency, grade, outcome, relation with study treatment, all considering the total number and proportion based on the safety population. Treatment-related AEs: An event is assessed as related to study treatment when there is a reasonable possibility that study treatment caused the event. Reasonable possibility means there is evidence to suggest a causal relationship between study treatment and the event. This event is called a suspected adverse reaction. A suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any AE caused by a drug.

    Time frame: Throughout the study period, approximately a time frame of 2 years from start treatment

  5. Health-related quality of life (HRQoL)

    Health-related quality of life (HRQoL), assessed through the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) version 3, the head and neck specific module QLQ-H\&N35 and EuroQol EQ-5D. These questionnaires ask questions in relation to physical, emotional, social aspects and in general the level of functionality of patients diagnosed with cancer in the last week after application. The scores range from 0 to 100. Higher scores indicate better functioning for the patients, except for symptoms scales, in which high scores indicate greaters symptoms.

    Time frame: Throughout the study period, approximately a time frame of 2 years from start treatment

07

Study locations

16 of 17 sites recruiting
  • Hospital Clínico Universitario de Santiago de Compostela
    Santiago de Compostela, A Coruña 15706, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Instituto Catalán de Oncología - Badalona
    Badalona, Barcelona 08916, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Instituto Catalán de Oncología - Hospital Duran i Reynals
    Barcelona, Barcelona 08908, Spain
    Recruiting
    • A responsible person Selected by Sponsor, · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Universitario Marqués de Valdecilla (Santander)
    Santander, Cantabria 39008, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Universitario Virgen de las Nieves
    Granada, Granada 18014, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Centro Oncológico de Galicia (La Coruña)
    A Coruña, La Coruña 15009, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Universitario Lucus Augusti
    Lugo, Lugo 27003, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Clínico San Carlos
    Madrid, Madrid 28040, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Universitario 12 de Octubre (Madrid)
    Madrid, Madrid 28041, Spain
    Withdrawn

    Not enrolling at this site.

  • Hospital Infanta Leonor (Madrid)
    Vallecas, Madrid 28031, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Regional Universitario de Málaga
    Málaga, Málaga 29010, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor,, M.D., Ph.D. · Principal investigator
  • Complejo Hospitalario de Navarra (Pamplona)
    Pamplona, Navarre 31008, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Complejo Hospitalario de Salamanca (Salamanca)
    Salamanca, Salamanca 37007, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Universitario de Canarias (La laguna)
    San Cristóbal de La Laguna, Santa Cruz de Tenerife 38320, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Universitario Virgen del Rocío (Sevilla)
    Seville, Sevilla 41013, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Universitario Virgen de Valme (Sevilla)
    Seville, Sevilla 41014, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Universitario de Toledo
    Toledo, Toledo 45007, Spain
    Recruiting
    • A responsible person Selected by Sponsor,, M.D., Ph.D. · Contactinvestigacion@mfar.net · +34 93 434 44 12
    • Principal investigator Selected by Sponsor,, M.D., Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2028, 40 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 40 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Mar 4, 2025
StartActual
Jun 18, 2025
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06856213
Lead sponsor
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Collaborators
Merck, S.L., Spain, MFAR
Responsible party
Sponsor
First posted
Mar 4, 2025
Start date
Jun 18, 2025
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Jun 4, 2026

Study contacts

Federico Nepote, M.D., PhD.
Contact
investigacio@mfar.net
+34 93 434 44 12
Marisa Duran Senior Clinical research proyect manager (TTCC)
Contact
mduran@ttccgrupo.com
0034690756714
Santiago Cabezas, M.D., Ph.D.
study chair · Hospital San Carlos, Madrid
Marc Oliva, M.D., Ph.D.
study chair · ICO-Hospitalet
Neus Basté, M.D
study chair · ICO-Badalona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion